BioSig Technologies, Inc.

Equities

BSGM

US09073N3008

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.37 ^USD	+5.38%		-2.84%	-71.16%

Apr. 16	BioSig Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 12	BioSig Technologies Inc. Issues Promissory Note to an Investor for $500,000	CI

Biosig Technologies, Inc. Enters into an Agreement with Sb Technology, Inc

September 05, 2023 at 04:52 pm EDT

On August 29, 2023, BioSig Technologies, Inc. entered into an agreement with SB Technology, Inc., a subsidiary of SandboxAQ (SandboxAQ). Pursuant to the Agreement, the Company has retained SandboxAQ to provide certain services for the Company in accordance with the terms and provisions of the Agreement.

Latest news about BioSig Technologies, Inc.

BioSig Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 16	CI
BioSig Technologies Inc. Issues Promissory Note to an Investor for $500,000	Mar. 12	CI
BioSig Technologies, Inc. announced that it has received $0.5 million in funding	Mar. 06	CI
Biosig Technologies, Inc. Announces Resignation of Kenneth L. Londoner as Chief Executive Officer	Feb. 28	CI
BioSig Technologies, Inc. Announces Executive Changes	Feb. 28	CI
Steve Buhaly Resigns as Chief Financial Officer of Biosig Technologies, Inc	Feb. 21	CI
Biosig Technologies, Inc. Announces Directorate Resignations	Feb. 21	CI
BioSig Announces Reduction of its Workforce	Feb. 20	CI
Biosig Technologies, Inc. Commences Workforce Reduction Consisted of the Departure of Sixteen Employees	Feb. 01	CI
BioSig Technologies, Inc. Announces Executive Departures	Feb. 01	CI
BioSig Technologies Undertaking 1-for-10 Reverse Stock Split	Jan. 31	MT
BioSig Technologies, Inc. announced that it has received $1.04 million in funding	Jan. 11	CI
BioSig Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Biosig Technologies, Inc. Appoints Fred Hrkac as Executive Vice President	Nov. 07	CI
Mayo Clinic-Phoenix Adopts Biosig Technologies, Inc.'s New Pure EP Subscription Model	Nov. 02	CI
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	Nov. 01	MT
Sector Update: Health Care Stocks Declining Wednesday Afternoon	Nov. 01	MT
BioSig Technologies Receives Five New Patents Covering Digital Signal Processing Technology; Shares Rise	Nov. 01	MT
BioSig Technologies, Inc. announced that it has received $0.597497 million in funding	23-10-24	CI
BioSig Technologies, Inc. announced that it expects to receive $0.597497 million in funding	23-10-11	CI
BioSig Technologies, Inc. announced that it has received $1.169715 million in funding	23-10-05	CI
BioSig Technologies, Inc. announced that it expects to receive $0.810201 million in funding	23-09-20	CI
BioSig Technologies, Inc. announced that it has received $0.549999 million in funding	23-09-11	CI
Biosig Technologies, Inc. Enters into an Agreement with Sb Technology, Inc	23-09-05	CI
BioSig Technologies, Inc. Achieves Infrastructure and Technology Progress in Development of Generative AI Platform for Hospitals	23-08-24	CI

Chart BioSig Technologies, Inc.

Duration

Period

More charts

Company Profile

BioSig Technologies, Inc. is a medical technology company focused on deciphering the bodyâs electrical signals, starting with heart rhythms. The Companyâs product, the PURE EP Platform, a non-invasive class II device, provides real-time signal visualization allowing physicians to perform highly targeted cardiac ablation procedures. Integrating with existing systems in the EP lab, PURE EP is designed to pinpoint even the complex signals to maximize procedural success and efficiency. The PURE EP System is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures, such as environmental lab noise from other equipment, signal saturation, slow signal recovery, and inaccurate display of fractionated potentials. PURE EP is a signal processing platform that combines advanced hardware and software to address known challenges associated to signal acquisition, to enable electrophysiologists to see more signals and analyze them in real-time.

Sector

Advanced Medical Equipment & Technology

More about the company

Income Statement Evolution

More financial data

Ratings for BioSig Technologies, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.37 USD

Average target price

7.5 USD

Spread / Average Target

+447.45%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
BIOSIG TECHNOLOGIES, INC.	-71.16%	15.34M
THERMO FISHER SCIENTIFIC	+8.07%	219B
DANAHER CORPORATION	+6.59%	183B
INTUITIVE SURGICAL, INC.	+11.26%	133B
BOSTON SCIENTIFIC CORPORATION	+26.57%	108B
SIEMENS HEALTHINEERS AG	+0.65%	63.06B
EDWARDS LIFESCIENCES CORPORATION	+13.35%	52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-0.62%	48.2B
AGILENT TECHNOLOGIES, INC.	-0.93%	40.37B
GE HEALTHCARE TECHNOLOGIES INC.	+11.54%	39.35B

Other Advanced Medical Equipment & Technology